We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Eutilex

News List

Samsung Biologics, National OncoVenture, and Eutilex Obtain IND Approval from FDA prnasia
January 27, 2021
Samsung Biologics announced another successful Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy, furthering the company's track record as a premiere CDO service provider in the ...
GenScript ProBio, Eutilex Enter Cancer Collaboration contractpharma
April 10, 2020
Partner on plasmid and virus process development and manufacturing for CAR-T programs.
GenScript ProBio and Eutilex Enter into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for CAR-T Programs prnasia
April 07, 2020
GenScript Biotech Corporation's CDMO business GenScript ProBio (hereinafter referred to as GenScript ProBio) and Eutilex Co., Ltd. (hereinafter referred to as Eutilex) committed to developing anti-cancer immunotherapy technology jointly announced that the
Samsung Biologics Signs CDO Deal with Eutilex firstwordpharma
March 21, 2019
Samsung Biologics signed on March 20 a contract development organization (CDO) agreement with Eutilex for developing cancer immunotherapy medicine.